Premium
Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MRSA pneumonia
Author(s) -
Saner Fuat H.,
Heuer Matthias,
Rath PeterMichael,
Gensicke Julia,
Radtke Arnold,
Drühe Nina,
Rüngeler EvaMarija,
Nadalin Silvio,
Malagó Massimo,
Broelsch Christoph E.
Publication year - 2006
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1002/lt.20885
Subject(s) - tigecycline , medicine , linezolid , liver transplantation , pneumonia , methicillin resistant staphylococcus aureus , salvage therapy , surgery , transplantation , staphylococcus aureus , antibiotics , vancomycin , chemotherapy , microbiology and biotechnology , genetics , bacteria , biology
Pulmonary infections are a significant cause of morbidity and mortality after liver transplantation. Infections with methicillin‐resistant Staphylococcus aureus (MRSA) have increased in the last 10 years. Mortality may exceed 80% in liver transplant recipients who develop MRSA pneumonia. A 57‐year‐old male following living‐donor liver transplantation developed a right‐sided MRSA pneumonia 6 weeks after transplantation, which required artificial ventilation for 14 weeks. Initially, pneumonia was treated with linezolid. However, after 12 days under current therapy, the infection spread out to both lungs. At that time. we initiated the treatment with tigecycline. Under this therapy, the patient could be cured from MRSA pneumonia and was extubated. We detected no tigecycline related hepatotoxic effect. In conclusion, this case suggests that tigecycline may be useful in the salvage therapy of pneumonia due to MRSA after linezolid failure. Liver Transpl 12:1689–1692, 2006. © 2006 AASLD.